Metabolic

Cagrilintide

Long-acting amylin analogue

Studied forWeight management1

Investigational cagrilintide; distinguish monotherapy from the CagriSema development program.

What does it do?

An investigational long-acting amylin analogue studied alone and with semaglutide. CagriSema results are combination evidence.

Approved & studied uses

Weight-management research

Monotherapy and semaglutide combination studies.

Community uses Reported, unvalidated

Weight

Obesity, diabetes-associated weight management and maintenance.

Metabolism

HbA1c, insulin sensitivity and post-meal glucose.

Appetite

Fullness, portions, food preferences and eating behavior.

Reasons people report using it; these do not establish benefit.15

Evidence limits

View research →

Research-market product identity, purity and formulation cannot be established from a publication.1

6 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Key safety information

All risks →

GI and injection-site effects

GI events affected 41–63% versus 32% with placebo; administration-site reactions also occurred.1

Investigational cagrilintide; distinguish monotherapy from the CagriSema development program.

Molecular information

3 15

Amino-acid sequence

Residue count only · sequence not verified3 15

An exact sequence has not been verified for this formulation.

Reference identity · not independently confirmed15

Length37 amino acids

Molecular weight · Da4409 Da

Formula, sequence notation & identity

Molecular formulaC₁₉₄H₃₁₂N₅₄O₅₉S₂3 15

Cagrilintide

PubChem rounded molecular weight for the parent structure; this does not establish a supplied vial’s identity or salt content.

Pep-Pedia identity details

37 amino acids · 4,409.01 Da

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH₂

Reference description; checked chemical identity above takes precedence when available.15

Pharmacokinetics

How long does it stay in the body?

Unverified reference estimateNot independently confirmed

Reference half-life7.5 days14

Route / formulationSource page: Injectable. Exact PK route not verified.

This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.

Elapsed time 7.5 d

50%of reference level

Illustrative scenario using an unverified reference estimate.

About 3% remaining after 37.5 d

Five half-lives in this estimated model. This is not a prediction of when effects stop.

Evidence and model details

Population: Not established by the reference estimate

Source’s stated attribution: Lau et al. J Med Chem 2021

Source’s reported peak time: 2 days. This has not been independently confirmed and is not used in the elimination curve.

100 × 2^{−time / half-life}. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.

What to expect

Study outcomes

Monotherapy reduced weight over 26 weeks

Mean weight reduction was 6.0–10.8% across cagrilintide doses versus 3.0% with placebo under the trial-product estimand.1

New phase 3 combination evidence

REDEFINE 5 studied the 2.4 mg/2.4 mg combination against semaglutide in Japan and Taiwan over 68 weeks. Its conclusions belong to the combination and population studied.2

Reported timelines

Reference & community

Weeks 1–2 / 4–8 / 12–26 / 26+

Reference sequence: GI adaptation; 2–5%; 10–15%; 15–23% weight loss. These are trial/combination-dependent claims, not monotherapy predictions.15

These are reported timelines, not a prediction of your response.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Topic

Primary goal

Fat loss89%

General wellness2%

Other: Weight loss 2%

Other: Appetite control2%

Other: Appetite suppressant 1%

The source hides 6 additional categories. Their labels and percentages are unavailable.

Number of responses to this question: not disclosed.

Source & limitations

The source displays “1301 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
This is a dated snapshot, not a live survey or current recommendation.

Protocols

Doses & schedules

Compare purpose, amount, route, frequency, and duration.

Scroll to compare all columns →

One row for each documented route and dose or dose range
Route	Dose	Frequency	Goal / evidence	Duration	References
SubQSubcutaneous	0.3 mg target	Once weekly	Phase 2 weight managementHuman study	26 weeks	1
Population Adults with overweight or obesity Context Trial escalation lasted up to six weeks; these are study-arm targets. Source dose wording 0.3, 0.6, 1.2, 2.4 or 4.5 mg target
SubQSubcutaneous	0.6 mg target	Once weekly	Phase 2 weight managementHuman study	26 weeks	1
Population Adults with overweight or obesity Context Trial escalation lasted up to six weeks; these are study-arm targets. Source dose wording 0.3, 0.6, 1.2, 2.4 or 4.5 mg target
SubQSubcutaneous	1.2 mg target	Once weekly	Phase 2 weight managementHuman study	26 weeks	1
Population Adults with overweight or obesity Context Trial escalation lasted up to six weeks; these are study-arm targets. Source dose wording 0.3, 0.6, 1.2, 2.4 or 4.5 mg target
SubQSubcutaneous	2.4 mg target	Once weekly	Phase 2 weight managementHuman study	26 weeks	1
Population Adults with overweight or obesity Context Trial escalation lasted up to six weeks; these are study-arm targets. Source dose wording 0.3, 0.6, 1.2, 2.4 or 4.5 mg target
SubQSubcutaneous	4.5 mg target	Once weekly	Phase 2 weight managementHuman study	26 weeks	1
Population Adults with overweight or obesity Context Trial escalation lasted up to six weeks; these are study-arm targets. Source dose wording 0.3, 0.6, 1.2, 2.4 or 4.5 mg target
SubQ	2.4 mg weekly	Once weekly	Weight Loss (Monotherapy)Reference report	Continuous treatment recommended for sustained effects	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable
SubQ	2.4 mg + semaglutide 2.4 mg	Once weekly	Weight Loss (CagriSema)Reference report	Continuous treatment recommended for sustained effects	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable
SubQSubQ with metformin	2.4 mg weekly	Once weekly	Type 2 Diabetes ManagementReference report	Continuous treatment recommended for sustained effects	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable
SubQ	0.25 mg · stage 1	Weekly increases over 16 weeks	Dose Escalation ProtocolReference report	Continuous treatment recommended for sustained effects	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source dose wording 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg Source tabs Injectable
SubQ	0.5 mg · stage 2	Weekly increases over 16 weeks	Dose Escalation ProtocolReference report	Continuous treatment recommended for sustained effects	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source dose wording 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg Source tabs Injectable
SubQ	1.0 mg · stage 3	Weekly increases over 16 weeks	Dose Escalation ProtocolReference report	Continuous treatment recommended for sustained effects	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source dose wording 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg Source tabs Injectable
SubQ	1.7 mg · stage 4	Weekly increases over 16 weeks	Dose Escalation ProtocolReference report	Continuous treatment recommended for sustained effects	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source dose wording 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg Source tabs Injectable
SubQ	2.4 mg · stage 5	Weekly increases over 16 weeks	Dose Escalation ProtocolReference report	Continuous treatment recommended for sustained effects	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source dose wording 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg Source tabs Injectable
SubQ	2.4 mg + SGLT2 inhibitor	Once weekly	Combination Diabetes TherapyReference report	Continuous treatment recommended for sustained effects	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable
SubQSubQ (REDEFINE 3 trial)	2.4 mg weekly	Once weekly	Cardiovascular Risk ReductionReference report	Continuous treatment recommended for sustained effects	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports15

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Injectable

Use period: Continuous treatment recommended for sustained effects
Break: Not applicable - continuous therapy for optimal efficacy

Reported timing

Same day weekly, preferably evening, with or without food

Side effects & safety

GI and injection-site effects

GI events affected 41–63% versus 32% with placebo; administration-site reactions also occurred.

Additional reported cautions

Reference reports15

Symptoms

Nausea, vomiting and diarrhea; inability to hydrate, severe back-radiating abdominal pain, allergy or abscess require assessment.

Formulation

Cloudiness, particles or gel texture are rejection signs, not a validated sterility test.

Evidence

Antibody, QT and tolerated-dose findings are trial-specific.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

10 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

Retatrutide

Caution reported

Compounded GI effects.15

Reference report · Pep-Pedia label: Use Caution

Insulin

Caution reported

Glucose/meal-timing effects.15

Reference report · Pep-Pedia label: Monitor Combination

Pramlintide

Avoidance reported

Duplicate amylin activity.15

Reference report · Pep-Pedia label: Avoid Combination

Semaglutide

Unverified pairing

CagriSema outcomes; not interchangeable with arbitrary mixtures.15

Reference report · Pep-Pedia label: Synergistic

Tirzepatide

Unverified pairing

No established safe combination.15

Reference report · Pep-Pedia label: Compatible

Liraglutide

Unverified pairing

Comparative trials do not establish coadministration.15

Reference report · Pep-Pedia label: Compatible

Metformin

Unverified pairing

Not blanket compatibility.15

Reference report · Pep-Pedia label: Compatible

SGLT2 inhibitors

Unverified pairing

Not blanket compatibility.15

Reference report · Pep-Pedia label: Compatible

Oral contraceptives

Unverified pairing

Reference 1-hour timing rule unvalidated.15

Reference report · Pep-Pedia label: Requires Timing

Other medicines and research compounds

Not established

No clinical interaction study for the exact proposed combination was verified; absence of evidence does not establish compatibility.4

Research context

Reconstitution

Product-specific information required

No universal bacteriostatic-water volume or validated preparation method is established for this entry.4

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Injectable

Pep-Pedia reports acidic-formulation requirements and a concern about fibril formation.

Solvents mentioned: Bacteriostatic water — source short-term claim / 0.6% acetic acid — source acidification claim
Reported parameters: Its claimed pH range is 3.5–4.5. · It describes BAC water at pH 5.5–6 for less than 30 days and 0.6% acetic acid to approach pH 4 for longer stability. · It reports refrigerated storage at 2–8°C and advises discarding cloudy or particulate material.

These source claims do not establish a validated home-acidification method or a shelf life for a particular vial.

Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearancePre-filled pen designReported appearancePharmaceutical grade purityReported appearanceFrozen storage stabilityReported appearanceExtended stability profileReported concernFibril formation at improper pHReported concernAggregation or precipitationReported concernTemperature excursionsReported variationpH-dependent stability - reconstitution concernsReported variationNot yet commercially available

Available forms

No verified packaging examples included.

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Refrigerated lifetime not established

The checked sources do not establish how long this research preparation remains stable and sterile after mixing.15

Full storage notes from Pep-Pedia

Injectable

Store frozen at -20°C, protect from light, do not shake

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Research findings

Human trials

Compound identity & other names

Studied alone and with semaglutide for weight management. Monotherapy and CagriSema results belong to different interventions and should be read separately.

Investigational cagrilintide; distinguish monotherapy from the CagriSema development program.

How it may work

Amylin/calcitonin receptor signaling affects satiety and gastric emptying.15

Monotherapy reduced weight over 26 weeks

Mean weight reduction was 6.0–10.8% across cagrilintide doses versus 3.0% with placebo under the trial-product estimand.

New phase 3 combination evidence

REDEFINE 5 studied the 2.4 mg/2.4 mg combination against semaglutide in Japan and Taiwan over 68 weeks. Its conclusions belong to the combination and population studied.

Source checks & newer research

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

REDEFINE 1 randomized 3,417 adults without diabetes. At 68 weeks, estimated weight change was −20.4% with CagriSema versus −3.0% placebo under the treatment-policy estimand. The often-quoted 22.7% is a different estimand, not cagrilintide monotherapy.

Phase 3 randomized trial; NEJM abstract checked16

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

REDEFINE 2 randomized 1,206 adults with type 2 diabetes. At 68 weeks, CagriSema weight change was −13.7% versus −3.4% placebo; 73.5% versus 15.9% reached HbA1c ≤6.5%. GI events affected 72.5% versus 34.4%.

Phase 3 randomized trial; NEJM abstract checked17

Cagrilintide: Sponsor report of randomized Phase 3 trial, 2,713 participants

Newer REIMAGINE 2 sponsor-reported treatment-regimen results at 68 weeks: CagriSema 2.4/2.4 mg changed HbA1c by −1.80 points and weight by −12.9%, versus −1.68 and −9.2% with semaglutide 2.4 mg, and −1.02 and −7.4% with cagrilintide 2.4 mg.

Sponsor report of randomized Phase 3 trial, 2,713 participants; report checked; journal abstract independently confirms design, PMID 4225185918

Research areas and evidence gaps

Weight-management research. Monotherapy and semaglutide combination studies.1

Research-market product identity, purity and formulation cannot be established from a publication.

Community reports Unvalidated

Weight discussions as described by Pep-Pedia.4

No representative survey, independently verified products, or controlled outcomes.

Search coverage and review status

The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.

Checked: 2026-10-12
Search: cagrilintide 2026 2025 REDEFINE trial site:pubmed.ncbi.nlm.nih.gov
Catalog: Pep-Pedia ↗ · 10 listed references retained

Targeted search, not an exhaustive systematic review.
Bibliography-only entries are retained for traceability and are not treated as verified findings.

AI-prepared summaries. Independent medical editorial review is pending.

References

Original sources and review status. Open a reference to read its summary.

18 sources

1Once-weekly cagrilintide for weight management in people with overweight and obesity: dose-finding phase 2 trialTrial · 2021 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

706-participant phase 2 study: dose-dependent weight reduction with cagrilintide; nausea and other GI effects were common.

Monotherapy reduced weight over 26 weeks

Mean weight reduction was 6.0–10.8% across cagrilintide doses versus 3.0% with placebo under the trial-product estimand.

Pep-Pedia bibliography · Checked 2026-10-12

Original source

2REDEFINE 5: cagrilintide-semaglutide versus semaglutide in Japan and TaiwanTrial · 2026 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

2026 phase 3a active-comparator study enrolled 331 participants. The intervention was cagrilintide plus semaglutide, not cagrilintide alone.

New phase 3 combination evidence

REDEFINE 5 studied the 2.4 mg/2.4 mg combination against semaglutide in Japan and Taiwan over 68 weeks. Its conclusions belong to the combination and population studied.

Additional research · Checked 2026-10-12

Original source

3PubChem: CagrilintideRegistry · 2026 · pubchem.ncbi.nlm.nih.govPrimary source checked

AI-PREPARED SUMMARY

Chemical registry identity, molecular formula and molecular weight; not clinical efficacy evidence.

Additional research · Checked 2026-10-12

Original source

4Pep-Pedia: Cagrilintide — community referenceCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Accessed October 12, 2026. Secondary descriptions and bibliography; community schedules are unvalidated reports, not recommendations.

Original source

5Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityTrial · Accessed 2026 · nejm.orgAbstract checked

AI-PREPARED SUMMARY

Pep-Pedia bibliography; reconciled with an existing checked primary-source record · Checked 2026-10-12

Original source

6Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesTrial · Accessed 2026 · nejm.orgAbstract checked

AI-PREPARED SUMMARY

Pep-Pedia bibliography; reconciled with an existing checked primary-source record · Checked 2026-10-12

Original source

7Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participantsResearch reference · Accessed 2026 · dom-pubs.onlinelibrary.wiley.comPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The single-dose cardiac study reportedly found no clinically meaningful QTc prolongation; it does not exclude all cardiovascular risks.

Reported population / model
Humans

Reported study details
4.5 mg single dose · 5 days · No clinically relevant QTc prolongation

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

8Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetesResearch reference · Accessed 2026 · sciencedirect.comPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: CagriSema reportedly produced 15.6% weight loss and a 2.2-point HbA1c reduction, outperforming the individual drugs in this trial.

Reported population / model
Humans

Reported study details
2.4 mg weekly · 32 weeks · 15.6% weight loss, 2.2% HbA1c reduction with CagriSema

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

9Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mgResearch reference · Accessed 2026 · sciencedirect.comPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The early combination study characterized exposure and tolerability with semaglutide; it is not proof of long-term safety.

Reported population / model
Humans

Reported study details
0.16-4.5 mg weekly · 20 weeks · Safety profile established

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

10Development of Cagrilintide, a Long-Acting Amylin AnalogueResearch reference · Accessed 2026 · pubs.acs.orgLinked reference · Not independently reviewed

REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

11Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptorsResearch reference · Accessed 2026 · nature.comLinked reference · Not independently reviewed

REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

12Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-AnalysisReview · Accessed 2026 · pmc.ncbi.nlm.nih.govLinked reference · Not independently reviewed

REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

13Cagrilintide: A Long-Acting Amylin Analog for the Treatment of ObesityResearch reference · Accessed 2026 · journals.lww.comLinked reference · Not independently reviewed

REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source

14Pep-Pedia: Cagrilintide — reported pharmacokineticsReference estimate; not independently verified human PKCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Lists a half-life of 7.5 days and a peak time of 2 days. Stated attribution: Lau et al. J Med Chem 2021. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.

Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12

Original source

15Pep-Pedia: Cagrilintide — route-specific referenceReference page checked; underlying claims require separate verification.Community · Checked 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.

Content coverage audit · Checked 2026-10-12

Original source

16Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityTrial · Accessed 2026 · nejm.orgAbstract checked

AI-PREPARED SUMMARY

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

Additional primary-source check · Checked 2026-10-12

Original source

17Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesTrial · Accessed 2026 · nejm.orgAbstract checked

AI-PREPARED SUMMARY

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Additional primary-source check · Checked 2026-10-12

Original source

18Cagrilintide: Sponsor report of randomized Phase 3 trial, 2,713 participantsSponsor report · Checked 2026 · novonordisk-us.comAbstract checked

AI-PREPARED SUMMARY

Cagrilintide: Sponsor report of randomized Phase 3 trial, 2,713 participants

Additional primary-source check · Checked 2026-10-12

Original source

What does it do?

Approved & studied uses

Weight-management research

Community uses Reported, unvalidated

Weight

Metabolism

Appetite

Evidence limits

Key safety information

GI and injection-site effects

Molecular information

Amino-acid sequence

How long does it stay in the body?

What to expect

Study outcomes

Monotherapy reduced weight over 26 weeks

New phase 3 combination evidence

Reported timelines

Weeks 1–2 / 4–8 / 12–26 / 26+

Experience

Duration of use

Age range

Gender

Primary goal

Effectiveness

Side effects

Dosage frequency

Would recommend

How discovered

Doses & schedules

Cycles & timing

Injectable

Reported timing

Side effects & safety

GI and injection-site effects

Additional reported cautions

Symptoms

Formulation

Evidence

Combinations & interactions

Retatrutide

Insulin

Pramlintide

Semaglutide

Tirzepatide

Liraglutide

Metformin

SGLT2 inhibitors

Oral contraceptives

Other medicines and research compounds

Reconstitution

Injectable

Available forms

Storage after mixing

Reconstituted research vials

Research findings

Monotherapy reduced weight over 26 weeks

New phase 3 combination evidence

Source checks & newer research

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Cagrilintide: Sponsor report of randomized Phase 3 trial, 2,713 participants

References